Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement

Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet